However, if β-cyclodextrin is administered at higher doses in animals via a subcutaneous route, it will cause a decrease in body weight gain, a decrease in liver weight, and nephrotoxicity, with an increase in kidney weight, proximal tubular nephrosis and cellular vacuolation